Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $381.44 Consensus PT from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) has received an average rating of "Hold" from the eleven analysts that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $381.44.

Several research analysts recently issued reports on MEDP shares. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. William Blair reissued an "outperform" rating on shares of Medpace in a research report on Tuesday, October 22nd. TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 target price on the stock. Finally, Truist Financial reduced their price target on shares of Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a report on Monday, October 14th.

Institutional Trading of Medpace

A number of institutional investors have recently made changes to their positions in MEDP. Pallas Capital Advisors LLC lifted its stake in shares of Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after buying an additional 2,101 shares during the period. Baillie Gifford & Co. lifted its position in Medpace by 175.6% during the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company's stock worth $4,966,000 after acquiring an additional 9,478 shares during the period. Barclays PLC grew its stake in Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Medpace by 6.3% in the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company's stock valued at $15,179,000 after purchasing an additional 2,675 shares during the period. Finally, CWA Asset Management Group LLC acquired a new position in shares of Medpace in the third quarter valued at about $1,306,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Performance

Medpace stock traded down $6.87 during trading hours on Thursday, hitting $354.10. The company had a trading volume of 287,927 shares, compared to its average volume of 208,882. The firm has a market cap of $11.01 billion, a P/E ratio of 31.01, a P/E/G ratio of 1.85 and a beta of 1.36. The company has a 50-day moving average price of $343.88 and a two-hundred day moving average price of $349.75. Medpace has a 1 year low of $302.01 and a 1 year high of $459.77.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.